Immunology conferences

This EMBO | EMBL Symposium brings cancer researchers together to examine how tumours spread and resist treatment. Topics include circulating and metastasis-initiating cells, invasion, epigenetic regulation, dormancy, cellular plasticity, immune escape and the tumour microenvironment. The programme connects biological mechanisms with imaging, single-cell and spatial profiling, computational analysis and disease models. The event runs from 10 to 13 November 2026 at the EMBL Advanced Training Centre in Heidelberg, with virtual participation available. Abstract submissions are closed. On-site registration closes on 29 September; virtual registration remains available until 3 November. Registration fees and the two booking routes are listed on the organizer page.

The meeting connects extracellular-vesicle biology with methods for isolation, characterisation and clinical translation. Sessions examine vesicle production and cargo sorting, communication between cells, neuroscience, immune modulation, disease biomarkers, bioengineering and therapeutic delivery. Studies range from proteomic profiling and diagnostic platforms to regenerative approaches and nucleic-acid therapies. An Education Day covers experimental design, isolation methods, MISEV guidance, career development and hands-on technology demonstrations; the scientific meeting includes oral presentations, posters and early-career research sessions. Programme times are Australia/Melbourne (AEDT, UTC+11). Education Day runs 09:30–16:30 on 24 November. The main meeting opens at 09:00 on 25 November, with the first scientific session at 09:30. Sessions begin at 09:00 on 26 and 27 November; the meeting ends at 13:15 on 27 November. In-person registration is AUD 952 for full members, AUD 1,152 for non-members, AUD 763 for junior members and AUD 532 for student members. Day rates are AUD 550 for members and AUD 650 for non-members; Education Day alone costs AUD 150. The conference dinner is separately priced.

The society’s 54th annual scientific meeting presents fundamental, translational and clinical immunology from Australia, New Zealand and the wider research community. Themes include infection, inflammation, autoimmunity, tumour immunology, immunometabolism, antigen presentation, B and T cells, mucosal and innate immunity, transplantation, vaccines and immunotherapies. The programme combines plenary lectures, symposia, special-interest-group workshops, a new-investigator session and poster presentations. The meeting takes place at QT Canberra from 30 November to 4 December. Paid registration offers member, non-member, student and day-attendance categories; full registration includes scientific sessions, exhibition and poster access, daily catering and a welcome reception. Abstract submissions have closed. Registration closes on 23 November at 23:59 AEST, as specified by the organizer.

Hosted by the American Society of Hematology, this meeting connects basic and translational blood research with clinical practice. Scientific sessions examine how genomic diagnostics, long-read sequencing and three-dimensional marrow models improve understanding of inherited disorders; how clonal selection and immune escape drive marrow failure; and how RNA regulation offers therapeutic targets in leukemia. AI-assisted flow cytometry, spatial multi-omics and epigenomic profiling link molecular mechanisms to diagnosis and risk stratification. Further sessions investigate stem-cell niches and immune control, tissue-resident T cells, iron homeostasis and erythrocyte metabolism, plasma-cell biology and treatment resistance. Structural and biophysical studies of coagulation, engineered vascular models and targeted imaging address thrombosis and fibrinolysis, including anti-PF4 disorders and safer platelet inhibition. Transplantation and cellular therapies extend into autoimmune disease. Didactic presentations, panels and questions accompany scientific, educational, oral-abstract and poster sessions. Programme times are America/Chicago (CST, UTC−6). The main meeting starts on 12 December with in-person ticketed expert sessions and poster walks at 08:00; Education/Scientific Program and oral-abstract sessions begin at 09:30. The Sunday plenary runs 14:00–16:00, Monday Education/Scientific Program sessions begin at 10:30, and Tuesday late-breaking abstracts begin at 07:30. Best of ASH ends at 13:00 on 15 December. Most sessions stream live; recordings remain available according to the purchased access tier. Friday workshops and satellite symposia are separate pre-meeting activities. Advance in-person or Real-Time virtual fees are USD 900 for active/international members, USD 1,700 for non-members, USD 175 for associate/student/resident members, USD 275 for non-member trainees and USD 800 for allied health professionals. The advance discount ends 21 October at 23:59 Pacific Time; non-member trainee advance rates continue through 1 December. Extended virtual access costs extra. Registration requires an ASH account and payment. In-person expert sessions require separate on-site tickets; trainee-only activities require the appropriate badge.

The conference focuses on molecular mechanisms of innate immunity and their relevance to disease and therapy. Researchers examine sensing pathways, self–nonself discrimination, immune activation and inhibition, connecting biochemical discoveries with drug development and interactions with adaptive immunity.

The meeting investigates cellular immune mechanisms during fungal infection and the technologies used to study them. Its programme connects barrier immunity, clinical immunology and laboratory discoveries, drawing comparisons with other infectious diseases and immune systems beyond mammals. Research presentations and discussion will examine how these connections can clarify host–fungus interactions. The oral-presentation abstract deadline was September 1, 2026; the later attendance application deadline is separate. Attendance applications are reviewed and capacity may fill before the application deadline.

The conference connects molecular immunology with therapeutic development in cancer. Researchers discuss resistance to checkpoint and cell-based therapies, targeting innate cells, emerging technologies and the challenge of translating mechanistic discoveries into clinical approaches.

A conference connecting fundamental cancer research from molecules and cells to tissues, organs and whole organisms. Sessions cover molecular mechanisms, enabling technologies, cell behaviour, and cancer’s interactions with immunity, metabolism and its environment. Early-career and established researchers can develop interdisciplinary collaborations; poster sessions and selected lightning talks provide opportunities to present research. Abstracts close on 30 October 2026, with decisions from 13 November. Early-bird rates ended on 11 September; standard rates apply through 27 November, followed by final admission rates from 28 November. Standard student tickets cost £125, academic/clinical/not-for-profit/healthcare tickets £175 and industry tickets £250; the listed LMIC rate is £50. Programme refreshments and lunches are included.

The 2027 Tropical Infectious Diseases Gordon Research Conference, "Host-Pathogen Interactions and Next-Generation Technologies for Translational Research", bridges mechanistic discoveries in host-pathogen biology with platform technologies, including spatial omics, artificial intelligence, nucleic acid vaccines, gene drives and precision drug delivery, to accelerate translation into diagnostics, treatments and vaccines against bacteria, fungi, parasites and viruses of global health relevance. Every session is balanced across all four pathogen classes, with topics ranging from precision vaccinology, nucleic acid platforms, immunometabolism and immunotherapy to transcriptomics, virulence factors and mechanisms of transmission and pathogenesis. The five-day meeting combines talks on unpublished work with extended discussion, poster sessions open to all career stages, and communal meals and free afternoons for informal exchange; attendance is by application.

Researchers examine interactions between pathogens and their vectors, seeking mechanisms that could inform disease control. The meeting connects vector biology, virology and other disciplines around challenges in malaria, arboviral infections and additional vector-borne diseases.

This meeting examines B-cell biology across infection, allergy, autoimmunity and cancer. The programme combines germinal-centre biology, immune memory and vaccination with emerging perspectives, connecting antibody mechanisms and structure with diverse functions of B cells. Abstract submission is closed; the organizer provides a waiting-list route for abstracts.

Researchers study how tissue context shapes immune-cell behaviour, communication and fate. The conference connects spatial transcriptomics, proteomics, imaging and computation with cellular atlases, examining local microenvironments and systemic influences in health and disease.

This meeting examines how interactions among glial cells and neurons influence nervous-system development, function and disease. Genomic and functional studies address microglia, astrocytes and myelinating cells, including diversity within each class and their contributions to circuits, behaviour and neurodegeneration. Programme themes cover neurodevelopmental and psychiatric disorders, ageing, human glia, glia-focused technologies, and interactions with immune cells and other glia. Talks, posters and extended discussion support exchange among established researchers and trainees. Applicants need a bachelor’s degree in science or engineering, or an accepted equivalent. Admission is selective and capacity may be reached before the application deadline.

The conference examines innovations in antibodies as medicines. Researchers compare conventional and emerging formats, conjugates, multiple-target approaches, selective targeting and computational design, connecting advances in antibody engineering with dosing, combinations and therapeutic applications.

This conference connects basic tuberculosis research with diagnosis, treatment and prevention. Researchers and clinicians discuss heterogeneity in host–pathogen interactions and how mechanistic findings can inform vaccines, care strategies and control of tuberculosis.

The 22nd Congress of the European Crohn’s and Colitis Organisation brings the global inflammatory bowel disease (IBD) community together to advance IBD care, research and education. Under the ECCO REACH strategy, the 2027 focus theme is “Causes of IBD”, bringing together science and technology to deepen understanding of the underlying causes of IBD. The scientific programme opens with the ECCO Lecture by Prof. Miles Parkes, “Pinpointing genetic, immunological and microbial contributors for IBD”, and includes more digital oral presentations, an expanded plenary and guided poster tours through more than 1,400 abstracts. The preceding educational programme features 15 courses, including the IBD Intensive Course, the S-ECCO IBD Masterclass, the ECCO Postgraduate Course in IBD, the ECCO Basic Imaging Workshop, the School for Clinical Trialists and the first ResCom Workshop. The scientific programme is live-streamed on the congress platform and available on demand.

The conference examines how microbial communities influence innate and adaptive immunity. Researchers connect molecular mechanisms with the possibility of microbiota-based medical interventions, comparing microbial contributions to immune function in health and disease.

Researchers discuss how immune defences develop early in life while limiting harmful inflammatory and autoimmune responses. Fundamental and clinical perspectives connect developmental mechanisms with infection, immunopathology and the design of vaccines for neonatal and paediatric populations.

The meeting examines development, differentiation and functions of myeloid cells. Researchers connect cellular lineages with microenvironmental and systemic signals, exploring how myeloid populations coordinate immunity and contribute to disease and immunotherapy.

This Keystone Symposium integrates fundamental mechanisms, precision diagnostics, and therapeutic development for Alzheimer's disease, non-Alzheimer dementias, and other neurodegenerative disorders. Joint programming with the Neural-Immune Interactions meeting connects disease mechanisms and clinical strategy with immune modulation of central nervous system biology.